13 results about "Protein S" patented technology

The invention belongs to the field of veterinary drugs, and relates to an avian infectious bronchitis virus antigen recombinant protein S-Trimer and a subunit vaccine thereof. The invention provides an avian infectious bronchitis virus antigen recombinant protein S-Trimer. The amino acid sequence of the antigen recombinant protein S-Trimer is as shown in SEQ ID No. 4. The invention provides an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer. The invention provides a chicken infectious bronchitis virus subunit vaccine. The subunit vaccine comprises a pharmaceutically acceptable carrier and an immune dose of the chicken infectious bronchitis virus antigen. The vaccine is high in safety, good in immunogenicity and stable in batches, and can provide complete protection for attacking the infectious bronchitis virus.

The invention discloses an anti-human MerTK antibody and an application of the anti-human MerTK antibody. The anti-human MerTK antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, a chimeric antigen receptor, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody, and applications of the nucleic acid, the recombinant expression vector, the transformant, the chimeric antigen receptor, the antibody drug conjugate, the pharmaceutical composition or the kit in preparation of drugs for preventing and / or treating tumors. The antibody disclosed by the invention is high in affinity, can specifically inhibit the interaction of the ligand Gas6-MerTK and the ligand protein S-MerTK at the same time, and does not inhibit the interaction of the ligand Tulp1-MerTK. And potential toxicity to the retina can be avoided when inhibition activity is exerted in vivo. In addition, the anti-human MerTK antibody provided by the invention can specifically and effectively inhibit phosphorylation of AKT in a Gas6-MerTK signal, and shows certain tumor inhibition activity in a mouse in-vivo model test.

The present application belongs to the field of veterinary drugs, and provides a recombinant protein S-Trimer of an infectious bronchitis virus antigen and a subunit vaccine therefor. Provided in the present application is a recombinant protein S-Trimer of an infectious bronchitis virus antigen, wherein the recombinant protein S-Trimer of the antigen has an amino acid sequence as set forth in SEQ ID No. 4. Also provided in the present application is an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer described above. The present application provides a subunit vaccine for an infectious bronchitis virus, wherein the subunit vaccine comprises a pharmaceutically acceptable carrier and an immunogenic amount of the infectious bronchitis virus antigen.

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and / or clotting.

The invention discloses an anti-MerTK antibody and an application of the anti-MerTK antibody. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, a chimeric antigen receptor, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody, and applications of the nucleic acid, the recombinant expression vector, the transformant, the chimeric antigen receptor, the antibody drug conjugate, the pharmaceutical composition or the kit in preparation of drugs for preventing and / or treating tumors. The antibody provided by the invention has high affinity, and can simultaneously block the interaction of the ligand GAS6-MerTK and the ligand protein S-MerTK, but does not block the interaction of the ligand TULP1-MerTK. And potential toxicity to the retina can be avoided when inhibition activity is exerted in vivo. In addition, the anti-human MerTK antibody provided by the invention can specifically and effectively inhibit phosphorylation of AKT in a Gas6-MerTK signal, and shows certain tumor inhibition activity in a mouse in-vivo model test.

A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from Table 1, 2 or 3 in a sample from a subject, where in the at least one protein may be selected from the list comprising: Beta-Ala-His dipeptidase, Apolipoprotein L1, Methanethiol oxidase, Vitamin K-dependent protein S, von Willebrand factor, Plasminogen, Selenoprotein P, Protein disulfide-isomerase A6 and Inter-alpha-trypsin inhibitor heavy chain H3, and (b) using the expression level to determine whether the subject has endometriosis.

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and / or clotting.

The invention relates to the technical field of in-vitro diagnostic reagent preparation, in particular to a high-stability protein S activity determination kit and a preparation method thereof, and the high-stability protein S activity determination kit comprises an activator, a substrate, a stop buffer and a standard substance; the activating agent contains snake venom protease, trehalose and the like and can activate protein S; the substrate contains a chromogenic substrate S-2366 and the like for chromogenic reaction; the stop solution contains glacial acetic acid and the like and is used for stopping reaction and stably developing; the standard substance contains recombinant protein S and the like for calibration; special components are added into the components to improve the stability, for example, zinc and magnesium ions are added into an activator to enhance the enzyme activity, and arginine is used as a substrate to inhibit hydrolysis; the components of the kit are independently packaged, and the pH and performance stable period at 2-8 DEG C is as long as 6 months. Through innovative formula design, the reagent stability and the detection accuracy are remarkably improved; special components enhance enzyme and substrate stability and reduce background interference; a standard product is optimized to improve the calibration precision; the preparation process guarantees batch-to-batch consistency, and is simple and convenient to operate, high in interference resistance and suitable for various clinical scenes.

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and / or clotting.

The present invention belongs to the technical field of nanomaterials and anti-tumor therapeutic drugs, and specifically relates to a nanomaterial for starvation therapy combined with copper death, as well as a preparation method and application thereof. The nanomaterial comprises a metal organic framework (MOF-199) wrapped around manganese dioxide (MnO2) nanoparticles, and glucose oxidase (GOx) is modified outside the MOF-199 shell. After the nanomaterial is internalized by cancer cells, on the one hand, glucose is consumed to achieve the purpose of starvation therapy. On the other hand, the MOF-199 shell is degraded by glutathione in the cancer cells, and the exposed MnO2 exerts catalase-like activity to catalyze the production of oxygen. At the same time, a surge in Cu(I) in the cell and oligomerization of lipoylated protein S-acetyltransferase (DLAT) lead to loss of mitochondrial function, resulting in copper death. The present invention not only achieves cancer treatment but also has important scientific significance.

Provided are a pharmaceutical composition for resisting infection with SARS-COV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-COV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and / or an adenovirus vaccine for preventing and / or treating an infection with SARS-COV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-COV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.

The application discloses application of a GmSAMS gene and protein in regulating soybean kernel quality, belongs to the technical field of genetic engineering, and particularly relates to application of the GmSAMS gene in regulating soybean kernel quality, wherein the nucleotide sequence of the GmSAMS gene is shown as SEQ ID NO. 1. The application can reduce the expression of a protein S-adenosylmethionine synthetase of the GmSAMS gene by silencing the GmSAMS gene, improve the protein content of soybean kernels, reduce the oil content of soybean kernels, reduce the total fatty acid content of soybean kernels, and make the soybean kernels smaller, so that the purpose of regulating the quality of soybean kernels is achieved.

Disclosed herein are methods of treating Von Willebrand Disease (VWD) in a subject in need. The methods include administering to the subject a therapeutically effective amount of a Protein S antibody, either subcutaneously or intravenously. The antibody may be administered using a body weight-based dosing regimen with one or more doses of about 0.1 mg / kg to about 10 mg / kg each, or a non-body weight-based dosing regimen with one or more doses of about 100 mg / dose to about 1000 mg / dose. The selected treatment methods result in an antibody plasma concentration of about 1μg / ml to about 200 μg / ml upon administration and increased thrombin generation and / or other pharmacodynamic biomarkers in the subject.